Clinical Trials

 

 

As new technologies and personalized vaccines become the norm, the dynamic of clinical trials has to evolve. This focused clinical development conference will allow you to showcase your services to those who are looking to run new trial models, need support in choosing and gaining approval for different clinical endpoints and want to understand how to get the best out of the information collected.

 

2018 AGENDA

 

Clinical Trials, Wednesday 4 April 2018

Clinical Trials
09:00

Chair’s opening remarks

Improving Immune Responses and Clinical Efficacy

Panel discussion
Clinical Trials
09:10

Novel adjuvants: What’s needed and how to get them approved?

  • Future of adjuvants – what is needed?
  • The need for a better strategy for a rational design
  • Developing adjuvants to improve existing vaccines & reduce the amount of vaccine antigen needed
  • New mechanism of adjuvant; Inducible adjuvant mediated by multiple, but specific pathways
Lynlee Burton
Clinical Trials
10:10

Early and late phase clinical trial design conundrums

  • Use of surrogate endpoints, differential efficacy / safety in diverse populations, accurate measures of exposure
10:40

Networking coffee break

Dr Steven Black
Clinical Trials
11:40

Limitations of randomized controlled clinical trials in vaccine development

Dr Adrian Wildfire
Clinical Trials
12:10

The problem with powering clinical trials PhII to PhIII, quo vadis?

  • Identifying contributing factors to late phase failure and to provide some insights into models for future Phase II trials to better evidence efficacy in the field
Clinical Trials
12:40

Immunosenescence: A growing population & an increasing unmet problem

1:10

Networking Lunch & Poster Session

Marty Anderson
Clinical Trials
2:40

Overcoming challenges in seasonal vaccine studies, including maternal immunization

Clinical need and justification for developing chronic infectious disease vaccines

Thomas Lingelbach
Clinical Trials
3:40

Development of a novel prophylactic vaccine for the prevention of Lyme Disease: PhI results on Valneva’s Lyme vaccine candidate VLA15 and development outlook

  • Background and medical need
  • Vaccine design including preclinical data for VLA15        
  • Phase I results and development outlook
4:10

Networking coffee break

Clinical Trials
4:40

PhIII HBV vaccine results

Clinical Trials
5:10

Strategies for global eradication – Do we need a prophylactic Hep C vaccine?

Clinical Trials
5:40

Encouraging results from clinical studies for a HIV vaccine

6:10

Chair’s closing remarks and close of congress day 2

6:15

Networking Drinks & Party

last published: 22/Nov/17 13:35

Clinical Trials, Thursday 5 April 2018

Clinical Trials
09:00

Chair’s opening remarks

Preventing Nosocomial Infections & Hard to Develop Vaccine

Dr Alan Cross
Clinical Trials
09:10

Using a core endotoxin vaccine (J5) to fight the increasing spread of multidrug-resistant (MDR) gram-negative bacterial (GNB) infections

  • Directing a vaccine against the conserved LPS core (lipooligosaccharide, LOS) region of GNBs as a highly effective and protective target
  • Two Ph1 trials showing how well-tolerated and non-reactogenic the vaccine was as well as high immunogenic levels when administered with CPG 7909 adjuvant
  • Future applications to generate antibodies for the treatment of a broad range of MDR GNB infections
  • How could the vaccine affect the microbiome?
Dr Annaliesa Anderson
Clinical Trials
09:40

Update on Group B streptococcal maternal immunization program

Dr Patricia Pietrobon
Clinical Trials
10:10

The road to a preventative vaccine for symptomatic Clostridium difficile infection (CDI)

10:40

Networking coffee break

Clinical Trials
11:30

Clinical progression in vaccine, anti-fungal and microbiome approaches to tackling candida albicans infections

Clinical Trials
12:00

Tools to assess and advance Group A Streptococcus (GAS) Vaccines

12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

last published: 22/Nov/17 13:35

 
 

DOWNLOAD DRAFT AGENDA

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

 

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

 

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

 

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071